Nyxoah Completes $50M Offering And Subsequent Sale Of Additional Shares, Raising $52.5M
Nyxoah Completes $50M Offering And Subsequent Sale Of Additional Shares, Raising $52.5M
Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.
Nyxoah打算将拟议发行的净收益用于美国的商业化前和商业化活动；（ii）继续收集临床数据，支持医生发起的与OSA患者治疗相关的临床研究项目；（iii）进一步资助与下一代Genio系统相关的研发活动，继续建立新技术管道，探索监测和诊断领域的潜在合作机会 OSA；和 (iv)用于其他一般公司用途，包括但不限于营运资金、资本支出、投资、收购（如果公司选择进行任何收购）以及合作。